SHADIEN ANTI-DOSTILO

Therapeutic Use Exemption (TUE) Checklist

CANADIAN CENTRE ETHICS NORT

CENTRECANADIEN
EL'ETHIQUESPORT

201-2723 chemin Lancaster Rd Ottawa ON Canada K1B 0B1 Tel/Tel + 1 613 521 3340 + 1 806 672 7775 Fax/Teléc + 1 613 521 3134 info@cces.ca www.cces.ca

Anaphylaxis

Prohibited Substances: Epinephrine and Glucocorticoids, Inhaled B2 Agonists

This checklist provides the athlete and their physician with a list of requirements for a TUE application. A TUE application must include a completed form and a medical file that confirms the diagnosis and prescription. If it is not possible to submit all mandatory items on the checklist, please have the treating physician explain why.

A complete application with a medical file will be reviewed by the CCES TUE Committee to assess whether it meets the criteria of the International Standard for Therapeutic Use Exemption (ISTUE). There are no guarantees that a TUE will be granted.

When an application is submitted without a complete medical file the CCES will advise the applicant which documents are missing and ask them to submit them.

TU	E application form must include:
	All sections completed in legible handwriting
	All information submitted in English or French
	A signature from the prescribing physician
	Athlete's signature in all appropriate sections
A le	etter from the athlete's prescribing physician confirming they were seen within the current year (see Annex 1 for example)
Me	dical reports should include details of:
	Medical history:
	1. onset, timeline of development of symptoms
	2. trigger mechanism (e.g., allergen, observation) if known
	3. comment on respiratory compromise, collapse, skin/mucosal reaction, gastrointestinal symptoms
	Physical examination (may be from emergency department, including blood pressure, respiratory rate, skin/mucosal
	reaction)
	Treatment prescribed: time and date, dosage, frequency, route of administration for each substance:
	a) Acute management (epinephrine/adrenaline and systemic glucocorticoids are prohibited in competition: nebulised
	beta-2-agonists are prohibited at all times; IV fluids are prohibited unless treatment is received in hospital)
	b) Maintenance/prevention: epinephrine autoinjector (prohibited in competition only)
Diagnostic tests:	
	Ambulance or emergency department/hospital records, where available
	Laboratory tests (e.g., tryptase levels), if relevant and available
	Photographic evidence of skin reaction, if relevant and available
	Skin prick test or other allergy testing

For more information about WADA's ISTUE criteria and additional information about the documentation to be submitted, please visit <u>WADA's TUE Physician Guidelines – Anaphylaxis</u>.